1.Enciclopedia Médica en Español. Acccidente cerebrovascular. Disponible en: http://www.nlm.nih.gov/medlineplus/spanish/ency/article/000726.htm 2.Accidente Cerebrovascular: Esperanza en la Investigación. Disponible en: (http://www.ninds.nih.gov/health_and_medical/pubs/accidente_cerebrovascular.htm) 3.Hoyert DL, Kochanek KD, Murphy SL. Deaths: Final Data for 1997. National Vital Statistics Reports 1999; 47(19). Hyattsville, Maryland: National Center for Health Statistics. 4.American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association. 1998. 5.National Institutes of Health, National Institute of Neurological Disorders and Stroke. Stroke: Hope Through Research. May 1999. Disponible en: www.ninds.nih.gov. 6.Cardiovascular Disease Surveillance, Stroke, 1980-1989. Atlanta, GA: Centers for Disease Control; 1994:69. 7.Anuario Estadístico MINSAP, 2003. 8.Sosa I, García JD, Subirós N, González C, Rodríguez Y, García JC. Alternativa terapéutica en la isquemia cerebral empleando la Eritropoyetina Humana Recombinante (rHu-EPOCIM) como neuroprotector. Revista CNIC Ciencias Biológicas 2006 (en prensa). 9.Encuesta Nacional de Factores de Riesgo. Instituto de Higiene, Epidemiología y Microbiología, 2000. 10.Navarro T, Henríquez D. Aspectos fisiopatológicos de la neuroprotección: en busca del tiempo perdido. Cuadernos de Neurología 2000; Vol. XXIV. Disponible en: http://escuela.med.puc.cl/paginas/publicaciones/Neurologia/cuadernos/2000/pub_01_2000.html 11.Arauz A, Murillo LM, Bonnin E. Neuroprotección en isquemia cerebral aguda. Estado actual e importancia clínica de la cascada isquémica. Revista Ecuatoriana de Neurología 2002; 11(3). Disponible en: http://www.medicosecuador.com/revecuatneurol/vol11_n3_2002/neuroproteccion.htm 12.Marinello J, Alós J, Carreño P, Olba L, Alexander C. Angiología 1995; 3:151-158. 13.The National Institute of Neurological Disorders and Stroke. rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587. 14.Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial. Molecular Medicine 2002; 8(8): 495–505. 15.Enfermedad cerebrovascular. Tratamiento de la enfermedad cerebrovascular oclusiva. Disponible en: http://www.iladiba.com.co/upr/1998/NO21998/HTM/ACV3.asp 16.Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, Sirén AL. Erythropoietin: Novel approaches to neuroprotection in human brain disease. Metabolic Brain Disease Dec 2004; 19(3/4):195-206. 17.Sirén AL, Ehrenreich H. Erythropoietin-a novel concept of neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001; 251:179-184. 18.Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al. From the cover: erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 19: 10526-31. 19.Giuseppe R, Luigi M. Hematologic Consequences of Renal Failure. Brenner and Rector’s. The Kidney, Sixth Edition 2000; 2079-2102. 20.Miyake T, Kung CK-H, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-5564. 21.Koury ST, Bondurat MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridisation. Blood 1988; 71:524-7. 22.Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 1999; 46: 543 547. 23.Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43: 40 49. 24.Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666 676. 25.Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994; 269: 19488 19493. 26.Eschbach JW, Nelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-163. 27.Goodnough LT, Monk TG, Andriole GL. Current concepts: erythropoietin theraphy. N Engl J Med 1997; 336: 933-938. 28.Allegro A, Galasso A, Siracusano L, Aloisi C, Corica F, Lagana A et al. Administration of recombinant erythropoietin determines increase of peripheral resistances in patients with hypovolemic shock. Nephron 1996; 74: 431-432. 29.Buemi M, Denuzzo G, Allegra A, Aloisi C, Squadrito F, Squadrito G et al. Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetyl-choline. Int J Microcirc 1995; 15: 283-286. 30.Buemi M, Allegra A, Aloisi C, Frisina N. Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects. Am J Nephrol 1991; 11: 281-283. 31.Kokot F, Wiecek A, Grzesczak W, Klepacka J, Klin M, Lao M. Influence of erythropoietin treatment on endocrine abnormalities in hemodialyzed patients. Contrib Nephrol 1989; 76: 257-270. 32.Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000; 401: 349-356. 33.Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clinical Science 2002; 103:275-282. 34.Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? The Neuroscientist 2004; 10(2):93-98. 35.Bartesaghi S, Marinovich M, Corsini E, Galli CL, Viviani B. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology 2005; 26: 923-928. 36.Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993; 268:11208–11216. 37.Marti HH, Gassmann M, Wenger RH, Kvietikova I, Morganti-Kossmann MC, Kossmann T, et al. Detection of erythropoietin in human cerebrospinal fluid: intrinsic erythropoietin production in the brain. Kidney Int 1997; 51: 416-418. 38.Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995; 92: 3717–3720. 39.Morishida E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116. 40.Bernaudin M, Bellail A, Marti HH, et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000; 30: 271–278. 41.Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-9743. 42.Yamaji R, Okada T, Moriya M, Naito M, Tauruo T, Miyatake K, Nakano Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239: 494-500. 43.Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98(7): 4044-4049. 44.Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 2000; 59:419–425. 45.Genc S, Akhisaroglu M, Kuralay F, Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 2002; 321:73–76. 46.Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952:128–134. 47.Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198(6):971–975. 48.Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: Changes after nerve injury. Faseb J 2001; 15:1804–1806. 49.Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci 2001; 16:110–113. 50.Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001; 276:39469–39475. 51.Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004; 22(2):105-119. 52.Sirén AL, Knerlich F, Poser W, Gleiter C, Brück W, Ehrenreich, H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001; 101:271–276. 53.Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res Aug 2004;63(2):208-216. 54.Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci, 2003 May 27; 100(11):6741-6746. 55.Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev Apr 2004;27(2):113-120. 56.Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002;91(438):36-42. 57.Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4635-40. 58.Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant 2002; 17 [Suppl 1]: 8–12. 59.Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2258-63. 60.Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005 Oct 14;387(1):5-10. 61.Buemi M, Corica FG, Calapai G, Salpietro FM, Casuscelli T, Sfacteria A, et al. In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage. Eur J Pharmacol 2000; 392: 31-34. 62.Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Ivas LA, Bauer C, Gassmann M. Localization of specific erythropoietin binding sites in defined areas of mouse brain. Proc Natl Acad Sci USA 1996; 92: 3717-3720. 63.Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Cristensen RD. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 1996; 40: 376-380. 64.Bohlius J, Langensiepen S, Schwarzer G, Engert A. Epoetin in the treatment ofmalignant disease: A comprehensive meta-analysis. Blood 2002; 100:3430A. 65.Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 2000; 1:11–31. 66.García JC, Miranda J. Carta al editor. Rev. CENIC Ciencias Biológicas 2005; 36(2). 67.Sosa I, García JC, García JD, Subirós N, González C, Rodríguez Y, et al. Eritropoyetina humana recombinante (rHu-EPO CIM) por vía nasal como neuroprotector en el ICTUS. Libro resumen Congreso Caribeño de ICTUS, Santiago de Cuba, 2005. 68.Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987 Jan 8; 316(2): 73-78. 69.Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175-1178. 70.Mayer G, Thum J, Cada EM, Estummvol HK, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988; 34: 525-528. 71.Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, et al. Exercise capacity, fistula blood flow and rheological studies during treatment with rHuEPO in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 319. 72.“EPREX” Product Monograph 2005. Disponible en: http://www.janssen-ortho.com/JOI/pdf_files/Eprex_E.pdf. 73.Eschbach JW, Egrie JC, Downing MR, et al. The Use of Recombinant Human Erythropoietin (r-HuEPO): Effect in End-Stage Renal Disease (ESRD). In: Friedman, Beyer, De Santo, Giordano, eds. Prevention of Chronic Uremia. Philadelphia, PA: Field and Wood Inc; 1989:148-155. 74.Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alpha on clinical outcome in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-34. 75.Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematological parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74. 76.Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100(7): 2303-2320. 77.Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005 Apr 20;23(12):2606-17. 78.Pérez-Oliva JF, Lagarde AM, Herrera R. Eficacia del tratamiento con eritropoyetina recombinante humana cubana (epocim), en pacientes anémicos hemodializados. Rev Hab C Médicas 2004; 3(10): 5-10. 79.Pérez-Oliva JF, Lagarde AM, Herrera R, Martínez AI, Raola ME, Magrans Ch. Broad Use of Cuban Recombinant Human Erythropoietin (ior-EPOCIM) in Dialysis Patients at the Institute of Nephrology. Medicc Review 2005; VII(5). Disponible en: http://www.medicc.org/medicc_review/0505/cuban-medical-literature-2.html 80.Hoke JF, Dyker AG, Barnaby RJ, Lees KR. Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. Eur J Clin Pharmacol 2000 Feb-Mar; 55(11-12):867-72. 81.IMAGES Study Group. Intravenous Magnesium Efficacy in Stroke Trial (IMAGES) [abstract]. Stroke 1999; 30:2259. 82.Bradford A. Intravenous Magnesium Efficacy in Stroke trial and MRI substudy (IMAGES & MR IMAGES) [abstract]. Cerebrovasc Dis 2000; 10:80. 83.Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; ii: 1017-1020. 84.Jacquot C, Ferragu-Haguet M, Lefebvre A, Berthelot JM, Peterlongo F, Castiagne JP. Recombinant erythropoietin and blood pressure (Letter to the editor). Lancet 1987; ii: 1083. 85.Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW. USA multicenter clinical trial with recombinant human erythropoietin (Amgen). In “Erythropoietin: from molecular structure to clinical application”. Baldamus CA, Scigalla P, Wieczorek L, Koch KM (eds). Contrib Nephrol, Basel, Karger 1989; 76: 160-165. 86.“PROCRIT”. Product Monograph 2005. Disponible en: http://www.procrit.com. 87.“EPO-C. Laboratorios CLAUSEN S.A.”. Monografía del producto 2005. Disponible en: http://www.clausen.com.uy/admin/Prospectos/epo-c.pdf. 88.“EPOGEN”. Product Monograph 2005. Disponible en: http://www.epogen.com. 89.Dessypris EN, Kranstz SB. Effect of pure erythropoietin on DNA synthesis by human marrow day 15 erythroid burst forming units in short-term liquid culture. Br J Haematol 1984; 56:295-306. 90.Rober G. Chronic renal failure. Goldman; Cecil textbook of medicine, 21st ed. 2000; 571-706. 91.Sowade B, Sowade O, Mocks J, Franke W, Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1998 Feb;1(2):303-14. 92.Editorial Review. Erythropoietin in the pathogenesis and treatment of the anemia of chroic renal failure. Kidney Int. 1997; 51: 622-630. 93.Colins AJ, Xia A, Fheben J. Trends in anemia treatment with Erythropoietin usage and patients outcomes (Abstract). Am J Kidney Dis 1998; 32(suppl 4): 133-141. 94.Singbartl G. Adverse events of erythropoietin in long-term and in acute short-term treatment. Clin Invest 1994; 72(suppl6): 36-43. 95.Pascual J. Efectos cardiovasculares de la Eritropoyetina. En: Valderrábano F. Eritropoyetina humana recombinante. Barcelona: MASSON 1998; 163-180. 96.Valderrábano F. Erythropoietin in cronic renal failure. Kidney Int 1996; 50: 1373-1391. 97.López J, Piera RL. Efecto beneficioso del tratamiento con Eritropoyetina Humana Recombinante. Fernando Valderrábano. España: Biblio STN. MASSON 1998; 119-179. 98.Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtypes of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41. 99.International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. Statistical Principles for Clinical Trials. Recommended for adoption at step 4 of the ICH process on February 1998 by the ICH Steering Committee.